Biotechnology

As SARS-CoV-2 moves fast through our global population, the pharmaceutical industry faces tremendous pressure to move even faster.

Commercial scale is not far-off for advanced therapy medicinal product (ATMP) facilities.

Manufacturers must produce a variety of ATMPs quickly and efficiently. Enter the multi-product ATMP facility.

Ensuring that patients receive novel medicines is a key driver for working to reduce the time it takes to design and build a new biopharmaceutical facility.

Interview with Niranjan Kulkarni, Senior Director, Allan Bream, Process Specialist, and Grace Linton, Process Architect at CRB that originally appeared in Cell and Gene Therapy Insights, on how commercial biopharma experience is shaping cell and gene therapy facility design.

So you want to build a new facility for advanced therapy manufacture? Before you start building, there is one essential element that you need to get right: site selection.

Applying a lean delivery approach to the design and construction of new facilities can reduce waste, lower costs and improve speed to market.

Water for injection (WFI) is used in the pharmaceutical industry to formulate parenteral drugs and for cleaning and other manufacturing operations. Reverse osmosis followed by a polishing step can be a more efficient and cost-effective solution for WFI production.

If cell and gene therapy products are to successfully reach patients and deliver transformative cures, then the industry will need more facilities capable of manufacturing them.